| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.05 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.062 | 0.05 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.05 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.06 |